Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
VacV Biotherapeutics logo — Developing oncolytic viruses as therapeutics for cancer

VacV Biotherapeutics

Developing oncolytic viruses as therapeutics for cancer

Founded 2022 United Kingdom London, United Kingdom 6 employees Seed Total: $3.00M Biotechnology, Health Care +1

General Information

Company Name VacV Biotherapeutics
Founded Year 2022
Location United Kingdom London, United Kingdom
Employees 6
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with VacV Biotherapeutics. To contact VacV Biotherapeutics, visit vacvbtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VacV Biotherapeutics compare?

A PDF of VacV Biotherapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VacV Biotherapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VacV Biotherapeutics

VacV Biotherapeutics, with the slogan "Developing oncolytic viruses as therapeutics for cancer," is a UK-based startup founded in 2022. The company, led by cancer immunotherapy experts Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall, and Dr. Peng Liu, is focused on developing innovative viral-based therapies for cancers. Their unique approach is based on the Vaccinia virus, which aims to stimulate a patient’s immune system to fight cancer while simultaneously destroying cancer cells. This cutting-edge approach offers advantages over existing immunotherapies, including minimized toxicity, higher specificity, and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time. VacV Biotherapeutics recently secured a $3.00M Seed Round investment on 01 January 2022 led by Proxima Ventures. The startup operates in the biotechnology, health care, and life sciences industries.

Business keywords: biotech, cancer immunotherapy, oncolytic virus, viral-based therapy, tumor-specificity, neurotoxicity, therapeutic potential, EEV production, biopharmaceuticals, treatment innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $3.00M 1
Proxima Ventures
Proxima Ventures
01 Jan 2022

VacV Biotherapeutics Alternatives & Competitors

View All Alternatives
VacV Biotherapeutics vs
Genelux
Genelux United States

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improvi...

Post-IPO Equity
34 employees
Biopharma, Biotechnology
VacV Biotherapeutics vs
Oncofactor Corporation
Oncofactor Corporation

A Seattle-based innovator in cancer treatments, disrupting tumor-immune system signaling pathways.

Venture round
1 employees
Biotechnology, Health Care
VacV Biotherapeutics vs
Forty Seven Inc.
Forty Seven Inc. United States

Helping Patients Defeat Their Cancer

Post-IPO Equity
17 employees
Biotechnology, Health Care
View all alternatives

FAQ About VacV Biotherapeutics

Developing oncolytic viruses as therapeutics for cancer
VacV Biotherapeutics was founded in 2022.
VacV Biotherapeutics is headquartered in London, United Kingdom.
VacV Biotherapeutics operates in Biotechnology, Health Care and Life Sciences. Its work centres on biotech, cancer immunotherapy, oncolytic virus and viral-based therapy.
VacV Biotherapeutics has approximately 6 employees.
VacV Biotherapeutics has completed 1 funding round, raising a total of $3.00M. The latest funding stage is Seed.
Top alternatives and competitors to VacV Biotherapeutics include Genelux, Oncofactor Corporation, Forty Seven Inc., Valo Therapeutics Ltd, Seneca Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VacV Biotherapeutics and Genelux are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VacV Biotherapeutics, https://bouncewatch.com/company/vacv-biotech, updated 13 April 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout